Xeris Biopharma Holdings (XERS) Common Equity (2020 - 2026)

Xeris Biopharma Holdings' Common Equity history runs 7 years deep, the most recent figure standing at $13.0 million for Q1 2026.

• Quarterly Common Equity rose 137.04% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (up 137.04% YoY) and the FY2025 annual result came in at $13.7 million, up 146.22% from the prior year.
• Common Equity was $13.0 million for Q1 2026 at Xeris Biopharma Holdings, down from $13.7 million in the prior quarter.
• Across five years, Common Equity topped out at $96.5 million in Q1 2022 and bottomed at -$35.1 million in Q1 2025.
• A 5-year average of $11.6 million and a median of $3.9 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity soared 2336.49% — and 2024, when it tumbled 832.81%.
• Xeris Biopharma Holdings' Common Equity stood at $45.2 million in 2022, then sank by 115.01% to -$6.8 million in 2023, then plunged by 336.67% to -$29.6 million in 2024, then jumped by 146.22% to $13.7 million in 2025, then decreased by 4.95% to $13.0 million in 2026.
• Business Quant data shows XERS's Common Equity at $13.0 million in Q1 2026, $13.7 million in Q4 2025, and -$861000.0 in Q3 2025.